{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:19:52Z","timestamp":1776244792098,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011322","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000}}],"reference-count":59,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011322.pub2","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T21:27:31Z","timestamp":1467235651000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer"],"prefix":"10.1002","volume":"2021","author":[{"given":"Rekha","family":"Wuntakal","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology; Barking, Havering & Redbridge University Hospitals NHS Trust; Romford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srividya","family":"Seshadri","sequence":"additional","affiliation":[{"name":"The Centre for Reproductive & Genetic Health; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Montes","sequence":"additional","affiliation":[{"name":"Medical Oncology; Guy's and St Thomas' Hospital NHS Foundation Trust; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff","family":"Lane","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology; Guy's and St Thomas' Hospital NHS Foundation Trust; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,6,29]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD011322.pub2-BIB0001|cit1","first-page":"116","article-title":"A randomised placebo-controlled efficacy and safety study of a sustained release LHRH agonist (Decapeptyl) in patients with advanced ovarian cancer","volume":"52","author":"Currie","year":"1994","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011322.pub2-BIB0002|cit2","first-page":"251","article-title":"Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer","volume":"13","author":"Du Bois","year":"2002","journal-title":"Annals of Oncology 2002"},{"issue":"7","key":"10.1002\/14651858.CD011322.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1452::AID-CNCR12>3.0.CO;2-Z","article-title":"Hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer study group","volume":"78","author":"Emons","year":"1996","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0004|cit4","first-page":"70:(abstr 123)","article-title":"A randomized comparison of decapeptyl and tamoxifen as treatment of progressive ovarian cancer","volume":"7(Suppl 2)","author":"Jager","year":"1993","journal-title":"Gynecological Endocrinology"},{"issue":"6B","key":"10.1002\/14651858.CD011322.pub2-BIB0005|cit5","first-page":"2639","article-title":"Comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer","volume":"15","author":"Jager","year":"1995","journal-title":"Anticancer Research"},{"issue":"3","key":"10.1002\/14651858.CD011322.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00003081-199309000-00025","article-title":"Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumours","volume":"36","author":"Adelson","year":"1993","journal-title":"Clinical Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomised, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30 (17)","author":"Aghajanian","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0008|cit8","first-page":"1","volume-title":"Emerging Therapeutic Targets in Ovarian Cancer","author":"Banerjee","year":"2011"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0009|cit9","unstructured":"Cancer Research UK Stages of ovarian cancer www.cancerresearchuk.org\/cancer-help\/type\/ovarian-cancer\/treatment\/stages-of-ovarian-cancer"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0010|cit10","unstructured":"Cancer Research UK Ovarian cancer report www.publications.cancerresearchuk.org\/cancerstats\/statsovarian 2011"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0011|cit11","unstructured":"Cancer Research UK Statistics on survival Cancer Research UK 2012"},{"issue":"5","key":"10.1002\/14651858.CD011322.pub2-BIB0012|cit12","first-page":"589","article-title":"Favorable effects of long-term therapy with gonadoliberin analogues in three patients with advanced and recurrent ovarian cancer","volume":"30","author":"Chudecka-Glaz","year":"2009","journal-title":"European Journal of Gynaecological Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011322.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2013.08.017","article-title":"Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer","volume":"89","author":"Colombo","year":"2014","journal-title":"Critical Reviews in Oncology\/Haematology"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0014|cit14","first-page":"717","article-title":"Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis","volume":"71","author":"Cramer","year":"1983","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0015|cit15","unstructured":"Common terminology criteria for adverse events ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Deeks JJ Altman DG Bradburn MJ (2001) Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis Systematic Reviews in Health Care: Meta-Analysis in Context 285 312. onlinelibrary.wiley.com\/advanced\/search\/results","DOI":"10.1002\/9780470693926.ch15"},{"issue":"4","key":"10.1002\/14651858.CD011322.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3802\/jgo.2013.24.4.293","article-title":"Staging of ovarian cancer: time to subdivide more?","volume":"24","author":"Denny","year":"2013","journal-title":"Journal of Gynecologic Oncology"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1210\/jcem-66-4-672","article-title":"Supression of postmenopausal ovarian steroidogenesis with luteinising hormone-releasing hormone agonist goserelin","volume":"66","author":"Dowsett","year":"1988","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomised phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruooe Ovariaikarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux pour kes Etudes des Cancers de I\u2019Ovaire (GINECO)","volume":"15","author":"Du Bois","year":"2009","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD011322.pub2-BIB0021|cit21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007565.pub2","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","author":"Elattar","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD011322.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/0960-0760(90)90457-V","article-title":"LHRH-Receptors and LHRH-Agonist treatment in ovarian cancer: an overview","volume":"37","author":"Emons","year":"1990","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/oxfordjournals.humrep.a138714","article-title":"The use of luteinising hormone-releasing hormone agonists and antagonists in gynaecological cancers","volume":"9","author":"Emons","year":"1994","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-642-59587-5_7","article-title":"Primary and salvage therapy with LHRH analogues in ovarian cancer","volume":"153","author":"Emons","year":"2000","journal-title":"Recent Results in Cancer Research"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0025|cit25","volume-title":"The M.D. Anderson Surgical Oncology Handbook","author":"Feig","year":"2006"},{"issue":"4","key":"10.1002\/14651858.CD011322.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0027|cit27","unstructured":"Ferlay J Soerjomataram I Ervik M Dikshit R Eser S Mathers C GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. globocan.iarc.fr\/Default.aspx"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/annonc\/mdt471","article-title":"Update on randomised trials on recurrent disease","volume":"24","author":"Gonzalez-Martin","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0029|cit29","unstructured":"Cochrane informatics and knowledge development department GRADEproGDT"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0030|cit30","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"National Cancer Institute Monographs"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/sj.bjc.6602752","article-title":"Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer","volume":"95","author":"Hassan","year":"2005","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0033|cit33","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0036|cit36","first-page":"71","article-title":"Cancer statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"Supp 10","key":"10.1002\/14651858.CD011322.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdt463","article-title":"Origin and molecular pathogenesis of ovarian high-grade serous carcinoma","volume":"24","author":"Kurman","year":"2013","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011322.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guidelines for diagnoses, treatment and follow up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD011322.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/cncr.23072","article-title":"A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission","volume":"110","author":"Levine","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011322.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bjc.1992.126","article-title":"A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer","volume":"65","author":"Lind","year":"1992","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3109\/00016349509008949","article-title":"Prognostic studies in cancer of the ovary and fallopian tube with emphasis on the CA 125 and c-erbB-2 oncogene. Summary of doctoral thesis","volume":"74","author":"Makar","year":"1995","journal-title":"Acta Obstetrica et Gynecologica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD011322.pub2-BIB0042|cit42","first-page":"2373","article-title":"Triptorelin (D-Trp-6-LHRH) in combination with carboplatin-containing polychemotherapy for advanced ovarian cancer: a pilot study","volume":"13","author":"Medl","year":"1993","journal-title":"Anticancer Research"},{"issue":"2","key":"10.1002\/14651858.CD011322.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00000421-199204000-00006","article-title":"A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group Study","volume":"15","author":"Miller","year":"1992","journal-title":"American Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011322.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343.pub3","article-title":"Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer","author":"Morrison","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"24","key":"10.1002\/14651858.CD011322.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/gyno.2002.6778","article-title":"No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer","volume":"86","author":"Paskeviciute","year":"2002","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0047|cit47","unstructured":"Pettersson F Annual Report on the Result of Treatment in Gynecological Cancer. Stockholm, Sweden FIGO 1994 22 83 102"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.seminoncol.2006.03.012","article-title":"Management of platinum-sensitive recurrent ovarian cancer","volume":"33","author":"Pfisterer","year":"2006","journal-title":"Seminars in Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011322.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00404-015-3697-y","article-title":"Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO","volume":"292","author":"P\u00f6lcher","year":"2015","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0050|cit50","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre The Cochrane Collaboration 2014"},{"issue":"3","key":"10.1002\/14651858.CD011322.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/07357909509094461","article-title":"A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer","volume":"13","author":"Ron","year":"1995","journal-title":"Cancer investigation"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0020-7292(03)00029-8","article-title":"GnRH analogues as an adjuvant therapy for ovarian cancer patients","volume":"81","author":"Rzepka-Gorska","year":"2000","journal-title":"International Journal of Gynaecology and Obstetrics"},{"issue":"75","key":"10.1002\/14651858.CD011322.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3802\/jgo.2010.21.2.75","article-title":"Maximal cytoreductive effort in epithelial ovarian cancer surgery","volume":"21","author":"Shih","year":"2010","journal-title":"Journal of Gynecologic Oncology"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0054|cit54","first-page":"212","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA: Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0055|cit55","unstructured":"Society of Gynaecologic Oncology New FIGO ovarian cancer staging guidelines, 2014 www.sgo.org\/wp-content\/uploads\/2012\/09\/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0056|cit56","first-page":"147","article-title":"Ovarian cancer: emerging molecular-targeted therapies","volume":"6","author":"Sourbier","year":"2012","journal-title":"Biologics: Targets and Therapy"},{"issue":"18","key":"10.1002\/14651858.CD011322.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/jnci\/djm163","article-title":"Cancer killer may be silent \u2018no more\u2019","volume":"99","author":"Twombly","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD011322.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"497429","DOI":"10.1155\/2010\/497429","article-title":"Treatment for recurrent ovarian cancer-at first relapse","volume":"2010","author":"Ushijima","year":"2010","journal-title":"Journal of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD011322.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIc or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"New England of Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011322.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T13:52:44Z","timestamp":1644328364000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011322.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,29]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011322.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,29]]}}}